United Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 1,468 Shares

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Martine A. Rothblatt sold 1,468 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $275.85, for a total transaction of $404,947.80. Following the completion of the sale, the director now owns 130 shares of the company's stock, valued at $35,860.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Up 0.5 %

UTHR traded up $1.25 during trading on Wednesday, reaching $276.44. 495,230 shares of the stock traded hands, compared to its average volume of 459,145. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $12.26 billion, a PE ratio of 13.14 and a beta of 0.54. The stock's 50-day moving average is $245.08 and its 200 day moving average is $233.08. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $279.98.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business's quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.86 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company's stock valued at $1,053,212,000 after purchasing an additional 20,373 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company's stock valued at $123,566,000 after purchasing an additional 9,962 shares during the period. LSV Asset Management raised its holdings in shares of United Therapeutics by 40.3% during the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company's stock valued at $121,641,000 after purchasing an additional 152,151 shares during the period. Norges Bank acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $100,519,000. Finally, Swedbank AB acquired a new position in shares of United Therapeutics during the first quarter valued at about $97,316,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on UTHR. HC Wainwright restated a "buy" rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a report on Friday, May 3rd. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 16th. Finally, Wedbush reiterated an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $309.44.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.